Covidien names Bryan Hanson group president, with oversight of all of the medical device company's businesses.
Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;
Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.
Medtronic ensures shareholders that the company remains beholden to (nearly) all U.S. corporate taxes as it shifts its headquarters overseas.
Lawmakers aim to prohibit companies from shifting their headquarters overseas in order to evade U.S. taxes, a measure that would apply retroactively to deals such as Medtronic's $43 billion acquisition of Covidien.
Covidien says it plans to launch the Emprint soft tissue ablation device for treating inoperable liver cancer during the 3rd quarter.
Covidien (NYSE:COV) said today that it's launching its Emprint soft tissue ablation system, aiming at the market for inoperable liver cancers.
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B